用COP方案治疗非何杰金氏淋巴瘤111例临床分析

Clinical Analysis of 111 Cases of Non—Hodgkin's Lymphoma Treated with COP

本文介绍了用COP方案治疗的111例非何杰金氏恶性淋巴瘤病人,CR23例,占20.7％;PR61例,占55％;RR75.7％,其中初治病人80例,RR82.5％,复治病人31例,RR58％,初治与复治病人有效率差异非常显著(P<0.01)。本组有B组症状者35例,RR60％;无B组症状者72例,RR84.7％;无B组症状与有B组症状者有效率差异非常显著(P<0.01)。本文Ⅰ、Ⅱ期病人32例,RR87.5％,Ⅲ、Ⅳ期病人79例,RR70.9％;Ⅰ、Ⅱ期病人较Ⅲ、Ⅳ病人有效率高,但差异不显著(P>0.05)。

111 cases of non—Hodgkin's lymphoma were treated with the protocol of the 3—drug combination of CTX, VCR, and PRED(COP). The overall rate of major objective responses(RR) was 75.5％. Of these 111 cases, 80 were new cases who had not received prior chemotherapy and had a RR of 82.5％; while 31 were old cases with a RR of 58.7％. SO, the difference in their effective rates was very significant(p<0.01). 35 cases had the symptoms of Group B and their RR was 60％; while the RR of patients in Group A who didn't have the symptoms seen in Group B was 84.7％. Again. the significant difference in their effective rates was observed(P<0.01). However. no significant difcrence in the effective rates was noted in this article between patients in Stages Ⅰ and Ⅱ and patients in Stages Ⅲ and Ⅳ. This was also true of the patients with bone marrow involvement compared with those who didn't have such involvement.